<\/p>\n
Syndopa<\/strong> is een immediate-release combination tablet of levodopa + carbidopa<\/strong> (110 mg (100\/10) and 275 mg (250\/25)) \u2014 the cornerstone treatment for Parkinson disease<\/strong>. Levodopa is converted to dopamine in the brain to replace what failing nigral neurones can no longer make; carbidopa blocks that conversion outside the brain so more levodopa reaches the central nervous system, with fewer peripheral side effects (nausea, vomiting, postural drops). Available in two strengths: 110 mg<\/strong> = 100 mg levodopa + 10 mg carbidopa (the lower carbidopa formula), and 275 mg<\/strong> = 250 mg levodopa + 25 mg carbidopa. The 25 mg carbidopa version is preferred for most patients because 75–100 mg of carbidopa daily is needed to fully saturate peripheral decarboxylase — below that level, peripheral side effects (nausea, hypotension) are common. Critical:<\/strong> never stop levodopa abruptly — risk of neuroleptic malignant-like syndrome<\/em>. Dose must be tapered.<\/p>\n<\/div>\n \ud83d\udce6 Elke bestelling is gedekt door onze Reshipment Assurance Policy<\/strong><\/a> \u2014 als uw pakket niet binnen 20 werkdagen arriveert, sturen wij het opnieuw.<\/p>\n Onze generieke medicijnen zijn afkomstig van WHO-GMP gecertificeerde fabrikanten en worden wereldwijd verzonden in discrete, eenvoudige verpakkingen \u2014 geen medicijnnaam op de buitenkant van het pakket. Betalingen met kaart worden verwerkt via een gereguleerde processor (betalingsoverzichten vermelden een gereguleerde kaartbetalingprocessor \u2014 nooit \u201cMedsBase\u201d of een medicijnnaam). Crypto en SEPA bankoverschrijvingen worden ook geaccepteerd. Elke bestelling wordt ondersteund door ons Reshipment Assurance Policy.<\/p>\n Syndopa is an oral tablet containing levodopa + carbidopa 110 mg (100\/10) and 275 mg (250\/25)<\/strong> in een immediate-release<\/strong> formulation. The combination has been the foundation of Parkinson disease therapy since the 1970s and remains the most effective single treatment for motor symptoms (bradykinesia, rigidity, tremor). It was originally marketed as Sinemet<\/strong>. Syndopa is manufactured by a WHO-GMP certified facility and is bioequivalent to the originator brand at the same strength.<\/p>\n Parkinson disease results from progressive loss of dopamine-producing neurones in the substantia nigra<\/em>. Levodopa<\/strong> is the immediate biochemical precursor of dopamine; unlike dopamine itself, it crosses the blood–brain barrier. Once inside the brain, surviving neurones decarboxylate it to dopamine, restoring synaptic dopamine levels and improving motor control.<\/p>\n The problem: when levodopa is given alone, >95% is converted to dopamine in peripheral tissues before it reaches the brain — causing severe nausea, vomiting and orthostatic hypotension, and forcing the use of huge doses. Carbidopa<\/strong> is a peripheral aromatic-amino-acid decarboxylase inhibitor. It does not cross the blood–brain barrier itself, but blocks the breakdown of levodopa in peripheral tissues. The result: a 4–5-fold reduction in the levodopa dose needed for the same brain effect, and far fewer GI\/cardiovascular side effects.<\/p>\n Syndopa is appropriate for adults with idiopathic Parkinson disease who need symptomatic motor relief, including:<\/p>\n Not appropriate for:<\/strong> patients with narrow-angle glaucoma, suspected melanoma or undiagnosed skin lesion, severe psychotic disorder, or current use of a non-selective MAO inhibitor (within 14 days).<\/p>\nWaarom bestellen bij MedsBase<\/h3>\n
What Is Syndopa?<\/h2>\n
How Does Syndopa Work?<\/h2>\n
Who Is Syndopa For?<\/h2>\n
\n
Dosing and Administration<\/h2>\n